Phase 1 trial of LYT-200, a galectin-9 directed mAb.

This open-label, multi-center study evaluates LYT-200 administered via IV infusion as monotherapy or combined with venetoclax and hypomethylating agents in patients with relapsed/refractory AML or high-risk MDS in a second-line+ setting. Sponsored by PureTech, the trial investigates safety, pharmacokinetics, and anti-tumor activity in this difficult-to-treat population.